A Widespread Population Study of Actual Medical Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Across Europe and Beyond Official Clinical Guidelines

被引：80

作者：

Cornu, Jean-Nicolas ^{[1
]}

Cussenot, Olivier ^{[1
]}

Haab, Francois ^{[1
]}

Lukacs, Bertrand ^{[1
]}

机构：

[1] Univ Paris 06, Dept Urol, Tenon Hosp, AP HP,Grp Hosp Univ EST, F-75970 Paris 20, France

来源：

EUROPEAN UROLOGY | 2010年 / 58卷 / 03期

关键词：

Benign prostatic hyperplasia; alpha-Blockers; Plants; 5-ARI inhibitors; Guidelines; Drugs; FOLLOW-UP; MEN; BPH; COUNTRIES; QUALITY;

D O I：

10.1016/j.eururo.2010.05.045

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background: The estimated prevalence of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) in men >50 yr of age is around 30%, similar in all industrialized countries. alpha(l)-Blockers and 5 alpha-reductase inhibitors (5-ARIs) are the two classes of drugs recommended by the European Association of Urology guidelines for the medical management of LUTS/BPH. Objective: To compare actual clinical practice across Europe with guidelines, we assessed the use of all BPH-related drugs (alpha(l)-blockers, 5-ARIs, and plants) among European countries with a large-scale quantitative and descriptive study. Design, setting, and participants: The amounts of BPH-related drugs prescribed in 19 European countries were obtained from the IMS Health database retrospectively from 2004 to 2008. Data were adjusted for each country by the number of people >50 yr of age. Measurements: We determined the "prescription index" related to BPH, defined for each drug per country by days of treatment sold per year divided by the number of men at risk divided by 365 d. Results and limitations: From 2004 to 2008, the yearly number of prescriptions was 11.6 million for 74 million people at risk. The global prescription index increased in all countries and was three-fold more important in southern countries than in northern ones. alpha(l)-Blockers are the most widely prescribed drugs, but the share of 5-ARIs is increasing. Phytotherapy prescription is country specific, varying from 0% to 40% of prescriptions and is not recommended by the guidelines. Conclusions: Major variations were seen among European countries concerning the prescriptions related to BPH, although the prevalence of the disease and the guidelines are similar. These results underline the importance of feedback from actual clinical practice. Analysis of actual prescription levels would complement evidence-based medicine as critical material for public health analysis, recommendations, and health insurance policies. (C) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

引用

页码：450 / 456

页数：7

共 17 条

[1] Surgical treatments for men with benign prostatic enlargement: cost effectiveness study [J].

Armstrong, Nigel ;

Vale, Luke ;

Deverill, Mark ;

Nabi, Ghulam ;

McClinton, Samuel ;

N'Dow, James ;

Pickard, Robert .

BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 :1187-1190

[2] The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study [J].

Boyle, P ;

Robertson, C ;

Mazzetta, C ;

Keech, M ;

Fourcade, R ;

Kiemeney, L ;

Lee, C .

BJU INTERNATIONAL, 2003, 92 (04) :409-414

[3] Can simple tests performed in the primary care setting provide accurate and efficient diagnosis of benign prostatic hyperplasia? Rationale and design of the Diagnosis Improvement in Primary Care Trial [J].

Carballido, J. ;

Fourcade, R. ;

Pagliarulo, A. ;

Cricelli, C. ;

Brenes, F. ;

Pedromingo-Marino, A. ;

Castro, R. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) :1192-1197

[4] Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries [J].

Fourcade, Richard-Olivier ;

Theret, Nathalie ;

Taieb, Charles .

BJU INTERNATIONAL, 2008, 101 (09) :1111-1118

[5] The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries [J].

Hutchison, Annie ;

Farmer, Richard ;

Verhamme, Katia ;

Berges, Richard ;

Vela Navarrete, Remigio .

EUROPEAN UROLOGY, 2007, 51 (01) :207-216

[6] Lower urinary tract - A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? [J].

Irani, J ;

Brown, CT ;

van der Meulen, J ;

Emberton, M .

BJU INTERNATIONAL, 2003, 92 (09) :937-942

[7] Simple case definition of clinical benign prostatic hyperplasia, based on international prostate symptom score, predicts general practitioner consultation rates [J].

Kok, Esther T. ;

Bohnen, Arthur M. ;

Jonkheijm, Rikkert ;

Gouweloos, Jochem ;

Groeneveld, Frans P. M. J. ;

Thomas, Siep ;

Bosch, J. L. H. Ruud .

UROLOGY, 2006, 68 (04) :784-789

[8] Management of symptomatic BPH in France: Who is treated and how? [J].

Lukacs, B .

EUROPEAN UROLOGY, 1999, 36 :14-20

[9] EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) [J].

Madersbacher, S ;

Alivizatos, G ;

Nordling, J ;

Sanz, CR ;

Emberton, M ;

de la Rosette, JJMCH .

EUROPEAN UROLOGY, 2004, 46 (05) :547-554

[10] Optimising the medical management of benign prostatic hyperplasia [J].

Marberger, M ;

Harkaway, R ;

de la Rosette, J .

EUROPEAN UROLOGY, 2004, 45 (04) :411-419

← 1 2 →